CD19 CAR-T Cells for Treatment-Refractory Autoimmune Diseases: The Phase 1/2 CASTLE Basket Trial

Researchers investigated the safety and efficacy of zorpocabtagene autoleucel, an autologous CD19 CAR-T cell product, in patients with treatment-resistant systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies.